LRI Investments LLC trimmed its stake in The Clorox Company (NYSE:CLX – Free Report) by 45.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 951 shares of the company’s stock after selling 800 shares during the quarter. LRI Investments LLC’s holdings in Clorox were worth $140,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Redwood Park Advisors LLC acquired a new position in Clorox in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new position in Clorox in the fourth quarter valued at $31,000. Wood Tarver Financial Group LLC acquired a new position in Clorox in the fourth quarter valued at $31,000. GKV Capital Management Co. Inc. acquired a new position in Clorox in the fourth quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Clorox in the fourth quarter valued at $33,000. 78.53% of the stock is owned by institutional investors and hedge funds.
Clorox Price Performance
CLX stock opened at $127.50 on Tuesday. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a 1 year low of $117.35 and a 1 year high of $171.37. The firm has a market cap of $15.71 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 3.12 and a beta of 0.51. The stock has a 50-day simple moving average of $128.06 and a 200-day simple moving average of $142.04.
Insider Activity
In related news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director owned 4,000 shares in the company, valued at $546,280. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.57% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently commented on the company. Citigroup dropped their target price on Clorox from $165.00 to $150.00 and set a “neutral” rating for the company in a research note on Monday, April 14th. JPMorgan Chase & Co. dropped their target price on Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research note on Tuesday, May 6th. Barclays reduced their target price on Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a report on Wednesday, May 7th. Jefferies Financial Group dropped their price target on Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Finally, Morgan Stanley dropped their price target on Clorox from $165.00 to $150.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Clorox currently has a consensus rating of “Hold” and an average target price of $148.92.
View Our Latest Analysis on CLX
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
See Also
- Five stocks we like better than Clorox
- Dividend Capture Strategy: What You Need to Know
- These 3 Undervalued Stocks Could Surge as Value Rotation Nears
- High Flyers: 3 Natural Gas Stocks for March 2022
- Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
- How to find penny stocks to invest and tradeĀ
- 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.